AHM-1: An Inclusion to the Arsenal of β-Lactam Resistance in Clostridioides difficile
ACS Infectious Diseases · 2025
DOI: 10.1021/acsinfecdis.4c00741 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Abirlal Mukherjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India. Hauptthemen laut MEDLINE: Clostridioides difficile, beta-Lactamases, beta-Lactam Resistance, Bacterial Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Science and Engineering Research Board, Department of Science and Technology, Ministry of Science and Technology, India, Indian Institute of Technology Roorkee.
Abstract (Originalsprache)
This study delves into a newly discovered MBL (metallo-β-lactamase) in Clostridioides difficile, a formidable pathogen known for causing nosocomial infections and exhibiting resistance to antimicrobial agents. The primary objective was to unravel its structure-function relationship. This research establishes the enzyme AHM-1 as a subclass B3-like MBL. Experimental results reveal that the enzyme's active site consists of two Zn2+ atoms exhibiting tetrahedral and trigonal bipyramidal coordination, similar to B1 and B3 MBLs. Notably, within its active site, it exhibits a lower binding capacity for other transition metal ions such as Fe2+, Mn2+, and Ni2+ compared to Zn2+. The zinc-binding sites of B1 and B3 MBLs contain strictly conserved His116-His118-His196 and Asp120-Cys221/His121-His263. The absence of all the conserved residues except His116, Asp120, and His121 in the Zn-binding site distinctly separates this enzyme from these two MBL subclasses. Conserved zinc binding motifs present in B1 and B3 MBLs are H-X-H-X-D and H-X-H-X-D-H, respectively. The presence of the H-X-D-X-D-H motif in the enzyme, similar to that in B3 enzymes, along with sequence and structural analysis, places this new enzyme closer to the enzymes belonging to the B3 subclass. This study also identifies the likely catalytic residues responsible for its β-lactamase activity, similar to B3 MBLs. In contrast to MBLs, this enzyme displays hydrolytic activity toward aztreonam. It also shows higher catalytic efficiency toward higher generation cephalosporins. This study thus underscores the significance of a novel enzyme with β-lactamase activity in Clostridioides difficile, highlighting its potential implications for clinical treatment due to its disparities from conventional MBLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.
- Division of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata 700010, India.
- Centre for Nanotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, India.
ORCID-Profile: Abirlal Mukherjee, Saugata Hazra
Förderung
- Science and Engineering Research Board
- Department of Science and Technology, Ministry of Science and Technology, India
- Indian Institute of Technology Roorkee
Zitieren
APA
Mukherjee, A., Barman, J., Ghosh, C., Adhikary, R., Dhankhar, K., Roy, P., Basu, S., & Hazra, S. (2025). AHM-1: An Inclusion to the Arsenal of β-Lactam Resistance in Clostridioides difficile. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00741
Vancouver
Mukherjee A, Barman J, Ghosh C, Adhikary R, Dhankhar K, Roy P, et al. AHM-1: An Inclusion to the Arsenal of β-Lactam Resistance in Clostridioides difficile. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.4c00741
BibTeX
@article{Mukherjee2025,
author = {Mukherjee, Abirlal and Barman, Jyoti and Ghosh, Chandrachur and Adhikary, Rajsekhar and Dhankhar, Kunal and Roy, Partha and Basu, Sulagna and Hazra, Saugata},
title = {AHM-1: An Inclusion to the Arsenal of β-Lactam Resistance in Clostridioides difficile},
journal = {ACS Infectious Diseases},
year = {2025},
doi = {10.1021/acsinfecdis.4c00741}
}
EUVIMED